penicillamine has been researched along with Retrolental Fibroplasia in 22 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants." | 9.14 | Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. ( Dogra, MR; Dutta, S; Gupta, A; Tandon, M, 2010) |
| "204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age (100 treated and 104 control subjects) were enrolled in a prospective controlled trial of the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP)." | 9.06 | Controlled trial of D-penicillamine to prevent retinopathy of prematurity. ( Alaka, O; Balla, G; Hatvani, I; Karmazsin, L; Kincses, E; Lakatos, L; Lakatos, Z; Oroszlán, G; Szabó, I, 1986) |
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 7.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "We enterally administered a 14-day course of 3-mercapto-D-valine (D-penicillamine) to five extremely low birth weight (ELBW) neonates, as a step toward assessing this therapy as a means of reducing the incidence or severity of retinopathy of prematurity (ROP)." | 7.73 | A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. ( Alder, SC; Baer, VL; Christensen, RD; Horn, JT; Lambert, DK; Richards, SC, 2006) |
| "To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants." | 5.14 | Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. ( Dogra, MR; Dutta, S; Gupta, A; Tandon, M, 2010) |
| "204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age (100 treated and 104 control subjects) were enrolled in a prospective controlled trial of the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP)." | 5.06 | Controlled trial of D-penicillamine to prevent retinopathy of prematurity. ( Alaka, O; Balla, G; Hatvani, I; Karmazsin, L; Kincses, E; Lakatos, L; Lakatos, Z; Oroszlán, G; Szabó, I, 1986) |
| "D-penicillamine was introduced to treat neonatal hyperbilirubinaemia in 1973 and to prevent retinopathy of prematurity in 1980." | 4.78 | [D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of phagocytes]. ( Csáthy, L; Lakatos, L; Maródi, L; Pataki, M; Szabó, I, 1991) |
| "To determine the effect of intraperitoneal and intravitreal D-penicillamine (DPA) on retinal neovascularization in a murine model of oxygen-induced retinopathy." | 3.77 | The effects of D-penicillamine on a murine model of oxygen-induced retinopathy. ( Ash, JD; Moreau, A; Siatkowski, RM; Yanovitch, TL, 2011) |
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 3.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "We enterally administered a 14-day course of 3-mercapto-D-valine (D-penicillamine) to five extremely low birth weight (ELBW) neonates, as a step toward assessing this therapy as a means of reducing the incidence or severity of retinopathy of prematurity (ROP)." | 3.73 | A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. ( Alder, SC; Baer, VL; Christensen, RD; Horn, JT; Lambert, DK; Richards, SC, 2006) |
| "A prospective controlled trial has recently been reported to show the effectiveness of D-penicillamine (DPA) in the prevention of retinopathy of prematurity (ROP) among infants less than 2000 g birth-weight." | 3.67 | One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period. ( Itzés, B; Lakatos, L; Oroszlán, G; Vekerdy-Lakatos, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (50.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qureshi, MJ | 1 |
| Kumar, M | 1 |
| Tandon, M | 1 |
| Dutta, S | 1 |
| Dogra, MR | 1 |
| Gupta, A | 1 |
| Siatkowski, RM | 1 |
| Yanovitch, TL | 1 |
| Ash, JD | 1 |
| Moreau, A | 1 |
| Christensen, RD | 2 |
| Alder, SC | 2 |
| Richards, SC | 2 |
| Horn, JT | 2 |
| Lambert, DK | 2 |
| Baer, VL | 2 |
| Vekerdy, Z | 2 |
| Lakatos, L | 16 |
| Balla, G | 4 |
| Oroszlan, G | 7 |
| Schmutz, N | 1 |
| Wiedmeier, SE | 1 |
| Burnett, J | 1 |
| Richards, M | 1 |
| Barraza, J | 1 |
| Hatvani, IL | 1 |
| Karmazsin, L | 6 |
| Makay, A | 1 |
| Hatvani, L | 1 |
| Hatvani, I | 4 |
| Phelps, DL | 4 |
| Matkovics, B | 1 |
| Watts, J | 1 |
| Watts, JL | 2 |
| Csáthy, L | 1 |
| Szabó, I | 3 |
| Pataki, M | 1 |
| Maródi, L | 1 |
| Alaka, O | 1 |
| Kincses, E | 2 |
| Lakatos, Z | 1 |
| Vekerdy-Lakatos, S | 1 |
| Itzés, B | 1 |
| Olubunmi, A | 1 |
5 reviews available for penicillamine and Retrolental Fibroplasia
| Article | Year |
|---|---|
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Randomized Controlled T | 2013 |
Neonatal oxygen toxicity and its prevention: D-penicillamine offers benefits without harmful side-effects.
Topics: Humans; Infant, Newborn; Oxygen; Oxygen Consumption; Penicillamine; Retinopathy of Prematurity; Vita | 1982 |
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of Prematur | 2000 |
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Topics: Chelating Agents; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Randomized Controlled T | 2001 |
[D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of phagocytes].
Topics: Humans; Hyperbilirubinemia; In Vitro Techniques; Infant, Newborn; Kidney; Liver; Penicillamine; Phag | 1991 |
3 trials available for penicillamine and Retrolental Fibroplasia
| Article | Year |
|---|---|
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial.
Topics: Administration, Oral; Double-Blind Method; Free Radical Scavengers; Humans; Infant, Newborn; Infant, | 2010 |
Controlled trial of D-penicillamine to prevent retinopathy of prematurity.
Topics: Clinical Trials as Topic; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Penicillamine; | 1986 |
[Prevention of retinopathy of premature infants with D-penicillamine].
Topics: Clinical Trials as Topic; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant | 1985 |
14 other studies available for penicillamine and Retrolental Fibroplasia
| Article | Year |
|---|---|
The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Chelating Agents; Disease Models, Animal; Humans; Infant, Newborn; Inject | 2011 |
A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates.
Topics: Birth Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; F | 2006 |
An international replication, and the need for long term follow up studies.
Topics: Adult; Humans; Infant, Newborn; Penicillamine; Randomized Controlled Trials as Topic; Reproducibilit | 2006 |
D-Penicillamine administration and the incidence of retinopathy of prematurity.
Topics: Bilirubin; Chelating Agents; Creatinine; Female; Humans; Incidence; Infant, Newborn; Male; Neutropen | 2007 |
Penicillamine and retinopathy of prematurity.
Topics: Humans; Infant, Low Birth Weight; Infant, Newborn; Penicillamine; Retinopathy of Prematurity | 1983 |
[Mechanism of action of penicillamine D in the neonatal period].
Topics: Age Factors; Animals; Birth Weight; Humans; Infant, Newborn; Jaundice, Neonatal; Penicillamine; Rats | 1983 |
Experimental data on the prevention of retrolental fibroplasia by D-penicillamine.
Topics: Animals; Antioxidants; Choroid; Humans; Infant, Newborn; Liver; Lung; Macrophages; Oxygen Consumptio | 1980 |
Penicillamine, vitreous proliferation, and retinopathy of prematurity.
Topics: Eye Injuries; Glucocorticoids; Humans; Infant, Newborn; Penicillamine; Retinopathy of Prematurity; V | 1982 |
Penicillamine, vitreous proliferation, and retinopathy of prematurity.
Topics: Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of Prematurity | 1982 |
D-penicillamine in the prevention of retrolental fibroplasia.
Topics: Cell Membrane; Free Radicals; Humans; Infant; Infant, Newborn; Jaundice, Neonatal; Lipid Peroxides; | 1982 |
Transgenic mice model of ocular neovascularization driven by vascular endothelial growth factor (VEGF) overexpression.
Topics: Animals; Disease Models, Animal; Endothelial Growth Factors; Humans; Infant, Newborn; Lymphokines; M | 1998 |
International replications, anyone?
Topics: Chelating Agents; Copper; Humans; Infant, Newborn; Infant, Premature; Penicillamine; Retinopathy of | 1999 |
D-penicillamine and retinopathy of prematurity.
Topics: Humans; Infant, Newborn; Penicillamine; Retinopathy of Prematurity | 1988 |
One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period.
Topics: Child Development; Follow-Up Studies; Growth; Hospitalization; Humans; Infant Mortality; Infant, New | 1987 |